Figure 1From: Yokukansan (TJ-54) for treatment of pervasive developmental disorder not otherwise specified and Asperger’s disorder: a 12-week prospective, open-label study Changes in mean CGI-S scores. CGI, Clinical Impressions-Severity; BL, baseline.Back to article page